Empyrean Capital Partners LP Has $9.52 Million Holdings in Oaktree Acquisition Corp. III Life Sciences $OACC

Empyrean Capital Partners LP lifted its position in shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) by 20.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 900,000 shares of the company’s stock after buying an additional 150,000 shares during the quarter. Empyrean Capital Partners LP’s holdings in Oaktree Acquisition Corp. III Life Sciences were worth $9,522,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of OACC. Clear Street Group Inc. acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the third quarter worth $231,000. Readystate Asset Management LP acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the third quarter worth $262,000. Radcliffe Capital Management L.P. acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the second quarter worth $856,000. UBS Group AG grew its holdings in Oaktree Acquisition Corp. III Life Sciences by 987,110.0% in the third quarter. UBS Group AG now owns 98,721 shares of the company’s stock worth $1,038,000 after purchasing an additional 98,711 shares during the period. Finally, Verition Fund Management LLC grew its holdings in Oaktree Acquisition Corp. III Life Sciences by 6.7% in the third quarter. Verition Fund Management LLC now owns 161,740 shares of the company’s stock worth $1,693,000 after purchasing an additional 10,117 shares during the period.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d)” rating on shares of Oaktree Acquisition Corp. III Life Sciences in a report on Thursday, April 2nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Oaktree Acquisition Corp. III Life Sciences Stock Performance

NASDAQ:OACC opened at $10.67 on Thursday. The firm has a fifty day simple moving average of $10.68 and a two-hundred day simple moving average of $10.65. Oaktree Acquisition Corp. III Life Sciences has a 12 month low of $10.30 and a 12 month high of $10.74.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last posted its quarterly earnings results on Thursday, March 26th. The company reported $0.08 EPS for the quarter.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.